Immunomodulatory Therapy for Oncology Clinicians
Source: Immunotherapy for Practicing Clinicians

Module

In this interactive CME-certified activity, Charles G. Drake, MD, PhD, provides an overview of the use of immunomodulatory agents in the treatment of patients with cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Utilize immunotherapies appropriately for the treatment of selected patients with cancer
  • Manage the adverse effects associated with immunotherapies used to treat cancer
  • Discuss clinical trials evaluating novel immunomodulatory agents with appropriate patients

Topics covered include:

  • Introduction to Immunomodulatory Approaches for Cancer Treatment
  • Vaccine Immunotherapy for Prostate Cancer
  • Blocking the Immune Checkpoint Molecule CTLA-4
  • Programmed Death 1: An Immune Checkpoint Molecule Important in Renal Cell Carcinoma, Melanoma, and NSCLC
  • Combining Immune Checkpoint Blockade With Conventional Chemotherapy in Lung Cancer
  • Combined Immune Checkpoint Blockade: The Future of Immunotherapy?
 

Faculty

  • Charles G. Drake
    MD, PhD

Credit Information

  • Release Date:
    July 10, 2012
  • Expiration Date:
    July 09, 2013
  • Physicians:
    maximum of 0.75 AMA PRA Category 1 Credits

Information on this Educational Activity

Disclosure of Conflicts of Interest

The Annenberg Center assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

 

Faculty

Charles G. Drake, MD, PhD


Associate Professor
Department of Oncology, Urology, and Immunology 
Johns Hopkins University
Baltimore, Maryland

Charles G. Drake, MD, PhD, has disclosed that he has received royalties and intellectual property rights from Bristol Myers-Squibb; has received consulting fees from Bristol Myers-Squibb, Dendreon, and Janssen, and has ownership interest in Amplimmune.
 

Staff

Timothy A. Quill, PhD


Managing Editor

Timothy A. Quill, PhD, has no significant financial relationships to disclose.
 

Gordon Kelley, 


Senior Clinical Editor

Gordon Kelley has no significant financial relationships to disclose.
 

Andrew D. Bowser, ELS, CCMEP


Editorial Director, Hematology/Oncology

Andrew D. Bowser, ELS, CCMEP, has no significant financial relationships to disclose.
 

Jim Mortimer, 


Senior Director, Oncology Programs and Partnership Development

Jim Mortimer has no significant financial relationships to disclose.
 

Edward King, MA


Vice President, Editorial
Clinical Care Options, LLC

Edward King, MA, has no significant financial relationships to disclose.
 

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following planners and managers, Laura Excell, ND, NP, MS, MA, LPC, NCC; Trace Hutchison, PharmD; Samantha Mattiucci, PharmD; Jan Schultz, RN, MSN, CCMEP; Patricia Staples, MSN, NP-C, CCRN and Gordon West, PhD, CCMEP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Annenberg Center, Postgraduate Institute for Medicine (PIM), Clinical Care Options, and activity supporters do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the Annenberg Center, PIM, Clinical Care Options, and activity supporters. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

 

Target Audience

This program is intended for physicians and other healthcare professionals who provide care for patients with cancer.


Goal

The goal of this activity is to increase participants’ understanding of the clinical relevance of immunotherapeutic strategies for the treatment of cancer.


Learning Objectives

Upon completion of this activity, participants should be able to:

  • Utilize immunotherapies appropriately for the treatment of selected patients with cancer
  • Manage the adverse effects associated with immunotherapies used to treat cancer
  • Discuss clinical trials evaluating novel immunomodulatory agents with appropriate patients
 

Physician Continuing Medical Education

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Commercial Support


This program is supported by an educational grant from Bristol-Myers Squibb.

 

Program Medium


This program has been made available online.

 

Site Requirements


  • Internet Explorer 7+, Firefox 3+, Safari 3+, or Chrome
  • JavaScript enabled
  • 1024x768+ screen resolution
  • Adobe Flash Player
 

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from July 10, 2012, through July 09, 2013:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 70% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME activities completed can be found on the "CME Manager" page. There are no costs/fees for this activity.